Fayez Sarofim & Co’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.9M | Sell |
2,460
-15
| -0.6% | -$11.5K | ﹤0.01% | 152 |
|
|
2025
Q4 | $1.91M | Sell |
2,475
-75
| -3% | -$50.9K | ﹤0.01% | 156 |
|
|
2025
Q3 | $1.43M | Sell |
2,550
-35
| -1% | -$19.8K | ﹤0.01% | 174 |
|
|
2025
Q2 | $1.36M | Sell |
2,585
-15
| -0.6% | -$8.37K | ﹤0.01% | 179 |
|
|
2025
Q1 | $1.65M | Sell |
2,600
-75
| -3% | -$51.6K | ﹤0.01% | 164 |
|
|
2024
Q4 | $1.91M | Hold |
2,675
| – | – | ﹤0.01% | 154 |
|
|
2024
Q3 | $2.81M | Hold |
2,675
| – | – | 0.01% | 138 |
|
|
2024
Q2 | $2.81M | Hold |
2,675
| – | – | 0.01% | 134 |
|
|
2024
Q1 | $2.57M | Sell |
2,675
-74
| -3% | -$70.4K | 0.01% | 137 |
|
|
2023
Q4 | $2.62M | Buy |
2,749
+74
| +3% | +$60.9K | 0.01% | 133 |
|
|
2023
Q3 | $2.2M | Hold |
2,675
| – | – | 0.01% | 136 |
|
|
2023
Q2 | $1.92M | Hold |
2,675
| – | – | 0.01% | 143 |
|
|
2023
Q1 | $2.2M | Buy |
2,675
+25
| +0.9% | +$18.9K | 0.01% | 140 |
|
|
2022
Q4 | $1.91M | Buy |
2,650
+300
| +13% | +$221K | 0.01% | 141 |
|
|
2022
Q3 | $1.62M | Hold |
2,350
| – | – | 0.01% | 150 |
|
|
2022
Q2 | $1.39M | Buy |
2,350
+50
| +2% | +$32.5K | 0.01% | 166 |
|
|
2022
Q1 | $1.61M | Buy |
2,300
+500
| +28% | +$316K | 0.01% | 173 |
|
|
2021
Q4 | $1.14M | Buy |
1,800
+1,300
| +260% | +$799K | ﹤0.01% | 199 |
|
|
2021
Q3 | $303K | Hold |
500
| – | – | ﹤0.01% | 275 |
|
|
2021
Q2 | $279K | Sell |
500
-300
| -38% | -$152K | ﹤0.01% | 293 |
|
|
2021
Q1 | $379K | Sell |
800
-383
| -32% | -$186K | ﹤0.01% | 232 |
|
|
2020
Q4 | $572K | Buy |
1,183
+125
| +12% | +$67.5K | ﹤0.01% | 207 |
|
|
2020
Q3 | $592K | Hold |
1,058
| – | – | ﹤0.01% | 185 |
|
|
2020
Q2 | $660K | Hold |
1,058
| – | – | ﹤0.01% | 176 |
|
|
2020
Q1 | $517K | Sell |
1,058
-100
| -9% | -$41.2K | ﹤0.01% | 174 |
|
|
2019
Q4 | $435K | Hold |
1,158
| – | – | ﹤0.01% | 210 |
|
|
2019
Q3 | $321K | Hold |
1,158
| – | – | ﹤0.01% | 217 |
|
|
2019
Q2 | $362K | Hold |
1,158
| – | – | ﹤0.01% | 212 |
|
|
2019
Q1 | $475K | Buy |
1,158
+183
| +19% | +$75.4K | ﹤0.01% | 188 |
|
|
2018
Q4 | $364K | Buy |
975
+150
| +18% | +$54.9K | ﹤0.01% | 194 |
|
|
2018
Q3 | $333K | Hold |
825
| – | – | ﹤0.01% | 212 |
|
|
2018
Q2 | $285K | Sell |
825
-46
| -5% | -$14.4K | ﹤0.01% | 219 |
|
|
2018
Q1 | $300K | Sell |
871
-38
| -4% | -$13.2K | ﹤0.01% | 217 |
|
|
2017
Q4 | $342K | Buy |
909
+46
| +5% | +$18.6K | ﹤0.01% | 208 |
|
|
2017
Q3 | $386K | Hold |
863
| – | – | ﹤0.01% | 196 |
|
|
2017
Q2 | $424K | Hold |
863
| – | – | ﹤0.01% | 198 |
|
|
2017
Q1 | $334K | Buy |
+863
| New | +$320K | ﹤0.01% | 213 |
|
Other funds holding REGN
VCM
N
Fayez Sarofim & Co's REGN Position: Q1 2026 in Review
Fayez Sarofim & Co reduced its Regeneron Pharmaceuticals (REGN) stake by 0.61% in Q1 2026, selling an estimated $11.5K and leaving 2,460 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #152.
Fayez Sarofim & Co first reported a position in REGN in Q1 2017 and has held it in 37 quarters since. The position peaked at $2.81M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Fayez Sarofim & Co held 2,460 shares of Regeneron Pharmaceuticals worth $1.9M as of Q1 2026.
- Fayez Sarofim & Co sold 15 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $11.5K.
- Regeneron Pharmaceuticals made up ﹤0.01% of Fayez Sarofim & Co's portfolio in Q1 2026, its #152 holding.
- Fayez Sarofim & Co first reported a position in Regeneron Pharmaceuticals in Q1 2017 and has held it in 37 quarters since.
- Fayez Sarofim & Co's Regeneron Pharmaceuticals position peaked at $2.81M in Q3 2024.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Fayez Sarofim & Co's 13F filing for Q1 2026, filed 15 May 2026.